Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 1,441 |
|
|||||
| News | - | ||||||
| Day High | 8.32 | Low High |
|||||
| Day Low | 8.00 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Oncternal Therapeutics Inc | ONCT | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.04 | 0.48% | 8.29 | 15:24:06 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 8.32 | 8.00 | 8.32 | 8.29 | 8.25 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 43 | 1,441 | US$ 8.16 | US$ 11,763 | - | 5.5656 - 13.14 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:00:00 | 8 | US$ 8.38 | USD |
Oncternal Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 24.54M | 2.96M | - | 785k | -39.48M | -13.34 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Oncternal Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ONCT Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 8.60 | 9.08 | 8.00 | 8.52 | 3,081 | -0.31 | -3.60% |
| 1 Month | 9.04 | 9.82 | 8.00 | 8.80 | 6,574 | -0.75 | -8.30% |
| 3 Months | 9.72 | 10.613 | 7.4819 | 9.05 | 8,113 | -1.43 | -14.71% |
| 6 Months | 7.00 | 13.14 | 5.5656 | 8.47 | 133,612 | 1.29 | 18.43% |
| 1 Year | 6.60 | 13.14 | 5.5656 | 7.52 | 172,721 | 1.69 | 25.61% |
| 3 Years | 126.60 | 137.798 | 5.22 | 47.31 | 466,764 | -118.31 | -93.45% |
| 5 Years | 137.40 | 211.20 | 5.22 | 76.47 | 668,494 | -129.11 | -93.97% |
Oncternal Therapeutics Description
| Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. |
